Nov 2 (Reuters) – Cerus Corp said on Monday a late-stage study showed that red blood cells treated with its blood-safety technology performed as well as conventional red blood cells in patients
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Jamie McGeever ORLANDO, Florida, Nov 2 (Reuters) - Oil prices tumbled on Monday on…
Nov 2 (Reuters) - Oracle plans to raise $20 billion through bond and share sales,…
Here are the top stories and upcoming coverage plans for Reuters text service as of…
(Adds CEO comments, outlook in paragraphs 3-8) Nov 2 (Reuters) - US shale producer Diamondback…
VIDEO SHOWS: REIGNING CHAMPIONS AL AHLI TAKE ON AL SADD IN THE ASIAN CHAMPIONS LEAGUE…
By Ann Saphir Nov 2 (Reuters) - Business demand for bank loans weakened last quarter…